Press Releases

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, PA and DURHAM, NC, September 28, 2022 — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has

$45 million clinical program funded by the Defense Threat Reduction Agency- Trial initiates clinical development effort in support of ACG-701 as a treatment for multiple life-threatening orphan pulmonary diseases, including cystic fibrosis RALEIGH-DURHAM, NC – June 15, 2022 – Aceragen, Inc., a clinical-stage biopharmaceutical company developing therapies for rare pulmonary and rheumatic diseases with high unmet